Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)

Historic Non-Current Debt for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to $498.3 million.

  • Ascendis Pharma A's Non-Current Debt rose 750.35% to $498.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $498.3 million, marking a year-over-year increase of 750.35%. This contributed to the annual value of $495.9 million for FY2024, which is 1322.46% up from last year.
  • Ascendis Pharma A's Non-Current Debt amounted to $498.3 million in Q3 2025, which was up 750.35% from $473.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Non-Current Debt ranged from a high of $598.2 million in Q3 2023 and a low of $112.1 million during Q4 2021
  • Its 5-year average for Non-Current Debt is $468.5 million, with a median of $481.4 million in 2024.
  • As far as peak fluctuations go, Ascendis Pharma A's Non-Current Debt surged by 25281.7% in 2022, and later tumbled by 2250.95% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Non-Current Debt (Quarter) stood at $112.1 million in 2021, then surged by 252.82% to $395.4 million in 2022, then rose by 10.78% to $438.0 million in 2023, then increased by 11.79% to $489.6 million in 2024, then increased by 1.77% to $498.3 million in 2025.
  • Its Non-Current Debt was $498.3 million in Q3 2025, compared to $473.2 million in Q2 2025 and $472.9 million in Q1 2025.